Beyond antiangiogenesis: Vascular modulation as an anticancer therapy-a review

Translational Oncology

Volumn 5, Issue 3, 2012, Pages 133-140

  Oronsky, Bryan T ^a   Scicinski, Jan J ^a   Reid, Tony ^b   Knox, Susan ^c  

^a RadioRx   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; COMBRETASTATIN A4 PHOSPHATE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; NITRIC OXIDE; RRX 001; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VASCULOTROPIN; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; COLORECTAL CANCER; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; PERSONALIZED MEDICINE; REVIEW; TUMOR BLOOD FLOW; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; VASCULAR MODULATION;

EID: 84862013407     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12118     Document Type: Article

References (64)

1. Guinebretiere JM (2009). Cancer is heterogeneous. J Clin Oncol 27, 2732; author reply 2734-2735.
2. Lai-Ming C, Wilson WR, and Baguley BC (2000). Inhibition of tumor blood flow. Methods Mol Med 25, 133-157.
3. Jeon KS, Na HJ, Kim YM, and Kwon HJ (2005). Antiangiogenic activity of 4-Omethylgallic acid from Canavalia gladiata, a dietary legume. Biochem Biophys Res Commun 330, 1268-1274.
4. Keshet E and Ben-Sasson SA (1999). Anticancer drug targets: approaching angiogenesis. J Clin Invest 104, 1497-1501.
5. Wang L, Schmitz V, Perez-Mediavilla A, Izal I, Prieto J, and Qian C (2003). Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther 8, 72-79.
6. Zetter BR (2008). The scientific contributions of M. Judah Folkman to cancer research. Nat Rev Cancer 8, 647-654.
7. Shan SQ, Rosner GL, Braun RD, Hahn J, Pearce C, and Dewhirst MW (1997). Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma. Br J Cancer 76, 429-437.
8. Gerhardt H and Betsholtz C (2003). Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 314, 15-23.
9. Benjamin LE, Hemo I, and Keshet E (1998). A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125, 1591-1598.
10. Mariani SM (2004). Antiangiogenesis cocktails-stirred or shaken? MedGenMed 6, 21.
11. Hall AP (2006). Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy. Toxicol Pathol 34, 763-775.
12. Hellstrom M, Kalen M, Lindahl P, Abramsson A, and Betsholtz C (1999). Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126, 3047-3055.
13. Franco M, Roswall P, Cortez E, Hanahan D, and Pietras K (2011). Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 118, 2906-2917.
14. Jiang X, Khan MA, Tian W, Beilke J, Natarajan R, Kosek J, Yoder MC, Semenza GL, and Nicolls MR (2011). Adenovirus-mediated HIF-1α gene transfer promotes repair of mouse airway allograft microvasculature and attenuates chronic rejection. J Clin Invest 121, 2336-2349.
15. Myers AL, Williams RF, Ng CY, Hartwich JE, and Davidoff AM (2010). Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J Pediatr Surg 45, 1080-1085.
16. Jain RK and Booth MF (2003). What brings pericytes to tumor vessels? J Clin Invest 112, 1134-1136.
17. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, Scheppke L, Stockmann C, Johnson RS, Angle N, et al. (2008). A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456, 809-813.
18. Lee JS, Semela D, Iredale J, and Shah VH (2007). Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte? Hepatology 45, 817-825.
19. Hamilton NB, Attwell D, and Hall CN (2010). Pericyte-mediated regulation of capillary diameter: a component of neurovascular coupling in health and disease. Front Neuroenergetics 2, 5.
20. König P, Groneberg D, Jäger R, and Friebe A (2011). NO-sensitive guanylyl cyclase is expressed in pericytes but absent from endothelial cells in the murine lung. BMC Pharmacology 11, P38.
21. Bergers G and Song S (2005). The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 7, 452-464.
22. Schlingemann RO, Rietveld FJ, Kwaspen F, van de Kerkhof PC, de Waal RM, and Ruiter DJ (1991). Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. Am J Pathol 138, 1335-1347.
23. McGown AT and Fox BW (1989). Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. Anticancer Drug Des 3, 249-254.
24. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, et al. (2005). Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115, 2992-3006.
25. Schwartz EL (2009). Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15, 2594-2601.
26. Horsman MR and Siemann DW (2006). Pathophysiologic effects of vasculartargeting agents and the implications for combination with conventional therapies. Cancer Res 66, 11520-11539.
27. Tozer GM, Prise VE, Lewis G, Xie S, Wilson I, and Hill SA (2009). Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin A-4 3-o-phosphate at clinically relevant doses. Clin Cancer Res 15, 3781-3790.
28. Davis PD, Tozer GM, Naylor MA, Thomson P, Lewis G, and Hill SA (2002). Enhancement of vascular targeting by inhibitors of nitric oxide synthase. Int J Radiat Oncol Biol Phys 54, 1532-1536.
29. OXiGENE, Inc. Zybrestat Background. Available at: www.oxigene.com/ our_science/zybrestat_background/. Accessed April 5, 2012.
30. Hama Y, Suzuki K, Shingu K, Fujimori M, Kobayashi S, Usuda N, and Amano J (1999). Three-dimensional structure of the micro-blood vessels in thyroid tumors analyzed by immunohistochemistry coupled with image analysis. Thyroid 9, 927-932.
31. Nathan P, Judson I, Padhani A, Harris A, Carden C, Smuythe D, Collins D, Leach M, Walicke P, and Rustin G (2008). A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 26, Abstract 3550.
32. 13C magnetic resonance spectroscopy. Mol Cancer Ther 9, 3278-3288.
33. Zhang J, Srikanchana R, Xuan J, Choyke P, Li K, and Wang YJ (2003). Partially independent component analysis of tumor heterogeneities by DCE-MRI. Proc SPIE 5032, 222-233.
34. Wan X, Shen N, Mendoza A, Khanna C, and Helman LJ (2006). CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1α/VEGF signaling. Neoplasia 8, 394-401.
35. Bates DO (2010). Vascular endothelial growth factors and vascular permeability. Cardiovasc Res 87, 262-271.
36. Korc M (2003). Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2, 8.
37. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, and De Bruijn EA (2004). Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56, 549-580.
38. Benjamin LE, Golijanin D, Itin A, Pode D, and Keshet E (1999). Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103, 159-165.
39. Raza A, Franklin MJ, and Dudek AZ (2010). Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol 85, 593-598.
40. Papetti M and Herman IM (2002). Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282, C947-C970.
41. Camp ER, Yang A, Liu W, Fan F, Somcio R, Hicklin DJ, and Ellis LM (2006). Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer. Clin Cancer Res 12, 2628-2633.
42. Ranpura V, Pulipati B, Chu D, Zhu X, and Wu S (2010). Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23, 460-468.
43. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, and Johnson DH (2010). Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28, 949-954.
44. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.
45. Jain RK, Tong RT, and Munn LL (2007). Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 67, 2729-2735.
46. Bergsland E and Dickler MN (2004). Maximizing the potential of bevacizumab in cancer treatment. Oncologist 9(suppl 1), 36-42.
47. Grepin R and Pages G (2010). Molecular mechanisms of resistance to tumour anti-angiogenic strategies. J Oncol 2010, 835680.
48. Snider KL and Maitland ML (2009). Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target Oncol 4, 67-76.
49. Aklilu M and Eng C (2011). The current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol 8, 649-659.
50. Lowenstein CJ and Michel T (2006). What's in a name? eNOS and anaphylactic shock. J Clin Invest 116, 2075-2078.
51. Dudzinski DM and Michel T (2007). Life history of eNOS: partners and pathways. Cardiovasc Res 75, 247-260.
52. Jain RK (1988). Determinants of tumor blood flow: a review. Cancer Res 48, 2641-2658.
53. Mi Q, Chen N, Shaifta Y, Xie L, Lu H, Liu Z, Chen Q, Hamid C, Becker S, Ji Y, et al. (2011). Activation of endothelial nitric oxide synthase is dependent on its interaction with globular actin in human umbilical vein endothelial cells. J Mol Cell Cardiol 51, 419-427.
54. Cardnell RJ and Mikkelsen RB (2011). Nitric oxide synthase inhibition enhances the antitumor effect of radiation in the treatment of squamous carcinoma xenografts. PLoS One 6, e20147.
55. Ng QS, Goh V, Milner J, Stratford MR, Folkes LK, Tozer GM, Saunders MI, and Hoskin PJ (2007). Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol 8, 111-118.
56. Sonveaux P, Jordan BF, Gallez B, and Feron O (2009). Nitric oxide delivery to cancer: why and how? Eur J Cancer 45, 1352-1369.
57. Zlotecki RA, Boucher Y, Lee I, Baxter LT, and Jain RK (1993). Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. Cancer Res 53, 2466-2468.
58. Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, and Knox S (in press). Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res.
59. 14C-RRx-001 in rats after a single intravenous administration and in blood from rats, dogs, monkeys, and humans. In 17th North American Regional ISSX Meeting, Atlanta, GA p. P81.
60. Fens MHAM, Larkin SK, Morris CR, Fitch B, Scicinski J, Oronsky B, and Kuypers FA (2011). NO or no NO, increased reduction of nitrite to nitric oxide by modified red blood cells. Blood (ASH Annual Meeting Abstracts) 118, 2125.
61. Sonveaux P (2008). Provascular strategy: targeting functional adaptations of mature blood vessels in tumors to selectively influence the tumor vascular reactivity and improve cancer treatment. Radiother Oncol 86, 300-313.
62. Ma J and Waxman DJ (2008). Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7, 3670-3684.
63. Sonveaux P, Dessy C, Brouet A, Jordan BF, Gregoire V, Gallez B, Balligand JL, and Feron O (2002). Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery. FASEB J 16, 1979-1981.
64. Shackney SE and Shankey TV (1995). Genetic and phenotypic heterogeneity of human malignancies: finding order in chaos. Cytometry 21, 2-5.